Sources

13 Total Sources

Amylyx Surges 56% After Phase 3 Drug Cuts Hypoglycemia Events 55%

Left29%

Center43%

Right14%

Far Right14%

Yahoo Finance2d ago

Amylyx Stock Surges 56% After Avexitide Phase 3 Success for Post-Bariatric Hypoglycemia

Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial | Reuters

Investor's Business Daily2d ago

Amylyx Stock Skyrockets on GLP-1 Drug's Hypoglycemia Reduction in Bariatric Surgery Patients

MedCity News2d ago

Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition - MedCity News

Seeking Alpha2d ago

Amylyx posts late-stage trial win for GLP-1 drug (AMLX:NASDAQ) | Seeking Alpha

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Endpoints News2d ago

Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia

ibtimes.com.au1d ago

Amylyx Pharmaceuticals Stock Soars 48% After Avexitide Hits All Endpoints in Pivotal Phase 3 Trial

StockTitan2d ago

Amylyx Phase 3 drug cuts severe hypoglycemia 55% | AMLX 8-K Filing

Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide - TipRanks.com

AMLX Stock Alert: Is Amylyx A Buy Now After Massive Blockbuster News?

Amylyx stock surges after avexitide Phase 3 trial success

Amylyx endocrine drug succeeds in key study for low blood sugar